Corona Remedies IPO
Live Updates, GMP, Subscription Data, and Financial Details
IPO Overview
Listed
Dates
Dec 08 to Dec 10 2025
Price Band
₹1008 - 1062
Current GMP
₹1470.0 (+38.42%)
Subscription
144.54 times
IPO Details
| IPO Date | Mon, Dec 8, 2025 to Wed, Dec 10, 2025 |
| Listing Date | Mon, Dec 15, 2025 |
| Face Value | ₹ 10 per share |
| Price Band | ₹1008 to ₹1062 |
| Issue Price | ₹1062 per share |
| Lot Size | 14 Shares |
| Sale Type | Offer For Sale |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE, NSE |
| Employee Discount | ₹ 54.00 |
| Total Issue Size | 61,74,051 shares (aggregating up to ₹ 655.37 Cr) |
| Share Holding Pre Issue | 6,11,60,088 shares |
| Share Holding Post Issue | 6,11,60,088 shares |
| BSE Script Code / NSE Symbol | 544644 / CORONA |
| ISIN | INE02ZQ01018 |
IPO Date
Mon, Dec 8, 2025 to Wed, Dec 10, 2025
Listing Date
Mon, Dec 15, 2025
Face Value
₹ 10 per share
Price Band
₹1008 to ₹1062
Issue Price
₹1062 per share
Lot Size
14 Shares
Sale Type
Offer For Sale
Issue Type
Bookbuilding IPO
Listing At
BSE, NSE
Employee Discount
₹ 54.00
Total Issue Size
61,74,051 shares (aggregating up to ₹ 655.37 Cr)
Share Holding Pre Issue
6,11,60,088 shares
Share Holding Post Issue
6,11,60,088 shares
BSE Script Code / NSE Symbol
544644 / CORONA
ISIN
INE02ZQ01018
IPO Subscription Details
| Anchor Investors | 1 |
| QIB (Ex Anchor) | 293.80 |
| Non-Institutional Buyers | 220.18 |
| bNII (bids above ₹10L) | 246.67 |
| sNII (bids below ₹10L) | 167.20 |
| Retail Investors | 30.39 |
| Employees | 15.56 |
| Total ** | 144.54 |
Anchor Investors
1
QIB (Ex Anchor)
293.80
Non-Institutional Buyers
220.18
bNII (bids above ₹10L)
246.67
sNII (bids below ₹10L)
167.20
Retail Investors
30.39
Employees
15.56
Total **
144.54
Day Wise Sub
| Day | QIB (Ex Anchor) | NII | NII (> ₹10L) | NII (< ₹10L) | Retail | EMP | Total |
|---|---|---|---|---|---|---|---|
| Day 1 Dec 8, 2025 | 0.00 | 0.84 | 0.53 | 1.45 | 0.96 | 1.48 | 0.67 |
| Day 2 Dec 9, 2025 | 1.76 | 28.37 | 29.02 | 27.07 | 6.90 | 4.37 | 9.96 |
| Day 3 Dec 10, 2025 | 293.80 | 220.18 | 246.67 | 167.20 | 30.39 | 15.56 | 144.54 |
DayDay 1
Dec 8, 2025
QIB (Ex Anchor)0.00
NII0.84
NII (> ₹10L)0.53
NII (< ₹10L)1.45
Retail0.96
EMP1.48
Total0.67
DayDay 2
Dec 9, 2025
QIB (Ex Anchor)1.76
NII28.37
NII (> ₹10L)29.02
NII (< ₹10L)27.07
Retail6.90
EMP4.37
Total9.96
DayDay 3
Dec 10, 2025
QIB (Ex Anchor)293.80
NII220.18
NII (> ₹10L)246.67
NII (< ₹10L)167.20
Retail30.39
EMP15.56
Total144.54
Day Wise GMP
| Date | Price | GMP | Estimate List Price |
|---|---|---|---|
| 15-12-2025 | 1062.00 | 342.5(32.25%) | 1404.5 |
| 14-12-2025 | 1062.00 | 342.5(32.25%) | 1404.5 |
| 13-12-2025 | 1062.00 | 295(27.78%) | 1357 |
| 12-12-2025 | 1062.00 | 330(31.07%) | 1392 |
| 11-12-2025 | 1062.00 | 291(27.40%) | 1353 |
| 10-12-2025 | 1062.00 | 295(27.78%) | 1357 |
| 09-12-2025 | 1062.00 | 270(25.42%) | 1332 |
| 08-12-2025 | 1062.00 | 262(24.67%) | 1324 |
| 07-12-2025 | 1062.00 | 290(27.31%) | 1352 |
| 06-12-2025 | 1062.00 | 305(28.72%) | 1367 |
| 05-12-2025 | 1062.00 | 365(34.37%) | 1427 |
| 04-12-2025 | 1062.00 | 365(34.37%) | 1427 |
| 03-12-2025 | 1062.00 | 307(28.91%) | 1369 |
| 02-12-2025 | 0(%) | (%) |
Date15-12-2025
Price1062.00
GMP342.5(32.25%)
Estimate List Price1404.5
Date14-12-2025
Price1062.00
GMP342.5(32.25%)
Estimate List Price1404.5
Date13-12-2025
Price1062.00
GMP295(27.78%)
Estimate List Price1357
Date12-12-2025
Price1062.00
GMP330(31.07%)
Estimate List Price1392
Date11-12-2025
Price1062.00
GMP291(27.40%)
Estimate List Price1353
Date10-12-2025
Price1062.00
GMP295(27.78%)
Estimate List Price1357
Date09-12-2025
Price1062.00
GMP270(25.42%)
Estimate List Price1332
Date08-12-2025
Price1062.00
GMP262(24.67%)
Estimate List Price1324
Date07-12-2025
Price1062.00
GMP290(27.31%)
Estimate List Price1352
Date06-12-2025
Price1062.00
GMP305(28.72%)
Estimate List Price1367
Date05-12-2025
Price1062.00
GMP365(34.37%)
Estimate List Price1427
Date04-12-2025
Price1062.00
GMP365(34.37%)
Estimate List Price1427
Date03-12-2025
Price1062.00
GMP307(28.91%)
Estimate List Price1369
Date02-12-2025
Price
GMP0(%)
Estimate List Price(%)
IPO Important Dates
| IPO Open Date | Mon, Dec 8, 2025 |
| IPO Close Date | Wed, Dec 10, 2025 |
| Tentative Allotment | Thu, Dec 11, 2025 |
| Initiation of Refunds | Fri, Dec 12, 2025 |
| Credit of Shares to Demat | Fri, Dec 12, 2025 |
| Tentative Listing Date | Mon, Dec 15, 2025 |
| Cut-off time for UPI mandate confirmation | 5 PM on Wed, Dec 10, 2025 |
IPO Open Date
Mon, Dec 8, 2025
IPO Close Date
Wed, Dec 10, 2025
Tentative Allotment
Thu, Dec 11, 2025
Initiation of Refunds
Fri, Dec 12, 2025
Credit of Shares to Demat
Fri, Dec 12, 2025
Tentative Listing Date
Mon, Dec 15, 2025
Cut-off time for UPI mandate confirmation
5 PM on Wed, Dec 10, 2025
IPO Lot Size
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 14 | ₹14,868 |
| Retail (Max) | 13 | 182 | ₹1,93,284 |
| S-HNI (Min) | 14 | 196 | ₹2,08,152 |
| S-HNI (Max) | 67 | 938 | ₹9,96,156 |
| B-HNI (Min) | 68 | 952 | ₹10,11,024 |
ApplicationRetail (Min)
Lots1
Shares14
Amount₹14,868
ApplicationRetail (Max)
Lots13
Shares182
Amount₹1,93,284
ApplicationS-HNI (Min)
Lots14
Shares196
Amount₹2,08,152
ApplicationS-HNI (Max)
Lots67
Shares938
Amount₹9,96,156
ApplicationB-HNI (Min)
Lots68
Shares952
Amount₹10,11,024
Financial Information
| Period Ended | 30 Jun 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Assets | 1,012.38 | 929.86 | 830.58 | 595.02 |
| Total Income | 348.56 | 1,202.35 | 1,020.93 | 891.10 |
| Profit After Tax | 46.20 | 149.43 | 90.50 | 84.93 |
| EBITDA | 71.80 | 245.91 | 161.19 | 135.03 |
| NET Worth | 607.02 | 606.34 | 480.41 | 408.52 |
| Reserves and Surplus | 545.86 | 545.18 | 419.25 | 347.36 |
| Total Borrowing | 106.65 | 62.70 | 134.14 | 2.33 |
Period EndedAssets
30 Jun 20251,012.38
31 Mar 2025929.86
31 Mar 2024830.58
31 Mar 2023595.02
Period EndedTotal Income
30 Jun 2025348.56
31 Mar 20251,202.35
31 Mar 20241,020.93
31 Mar 2023891.10
Period EndedProfit After Tax
30 Jun 202546.20
31 Mar 2025149.43
31 Mar 202490.50
31 Mar 202384.93
Period EndedEBITDA
30 Jun 202571.80
31 Mar 2025245.91
31 Mar 2024161.19
31 Mar 2023135.03
Period EndedNET Worth
30 Jun 2025607.02
31 Mar 2025606.34
31 Mar 2024480.41
31 Mar 2023408.52
Period EndedReserves and Surplus
30 Jun 2025545.86
31 Mar 2025545.18
31 Mar 2024419.25
31 Mar 2023347.36
Period EndedTotal Borrowing
30 Jun 2025106.65
31 Mar 202562.70
31 Mar 2024134.14
31 Mar 20232.33
Key Performance Indicator
| ROE | 27.50% |
| ROCE | 41.32% |
| Debt/Equity | 0.10 |
| RoNW | 24.65% |
| PAT Margin | 12.49% |
| EBITDA Margin | 20.55% |
| Price to Book Value | 10.71 |
ROE
27.50%
ROCE
41.32%
Debt/Equity
0.10
RoNW
24.65%
PAT Margin
12.49%
EBITDA Margin
20.55%
Price to Book Value
10.71
Peers Comparison
| Company Name | EPS (Basic) | EPS (Diluted) | NAV (per share) (Rs) | P/E (x) | RoNW (%) |
|---|---|---|---|---|---|
| Corona Remidies Limited | 24.43 | 24.43 | 99.14 | 24.65 | |
| Abbott India Ltd. | 665.62 | 665.62 | 1,992.14 | 45.17 | 33.41 |
| Alkem Laboratories Ltd | 181.11 | 181.11 | 1,002.37 | 31.39 | 18.07 |
| Eris Lifesciences Ltd | 25.85 | 25.81 | 209.73 | 61.81 | 12.21 |
| Glaxosmithkline Pharmaceuticals Ltd. | 54.76 | 54.76 | 115.19 | 46.87 | 47.54 |
| J.b.chemicals & Pharmaceuticals Ltd. | 42.45 | 41.56 | 220.88 | 42.60 | 19.21 |
| Mankind Pharma Limited | 49.28 | 49.20 | 352.51 | 45.77 | 13.89 |
| Pfizer Ltd. | 167.79 | 167.79 | 921.88 | 29.63 | 18.20 |
| Sanofi India Ltd. | 179.46 | 179.46 | 373.68 | 24.47 | 48.05 |
| Torrent Pharmaceuticals Ltd. | 56.47 | 56.47 | 224.28 | 65.91 | 25.18 |
Company NameCorona Remidies Limited
EPS (Basic)24.43
EPS (Diluted)24.43
NAV (per share) (Rs)99.14
P/E (x)
RoNW (%)24.65
Company NameAbbott India Ltd.
EPS (Basic)665.62
EPS (Diluted)665.62
NAV (per share) (Rs)1,992.14
P/E (x)45.17
RoNW (%)33.41
Company NameAlkem Laboratories Ltd
EPS (Basic)181.11
EPS (Diluted)181.11
NAV (per share) (Rs)1,002.37
P/E (x)31.39
RoNW (%)18.07
Company NameEris Lifesciences Ltd
EPS (Basic)25.85
EPS (Diluted)25.81
NAV (per share) (Rs)209.73
P/E (x)61.81
RoNW (%)12.21
Company NameGlaxosmithkline Pharmaceuticals Ltd.
EPS (Basic)54.76
EPS (Diluted)54.76
NAV (per share) (Rs)115.19
P/E (x)46.87
RoNW (%)47.54
Company NameJ.b.chemicals & Pharmaceuticals Ltd.
EPS (Basic)42.45
EPS (Diluted)41.56
NAV (per share) (Rs)220.88
P/E (x)42.60
RoNW (%)19.21
Company NameMankind Pharma Limited
EPS (Basic)49.28
EPS (Diluted)49.20
NAV (per share) (Rs)352.51
P/E (x)45.77
RoNW (%)13.89
Company NamePfizer Ltd.
EPS (Basic)167.79
EPS (Diluted)167.79
NAV (per share) (Rs)921.88
P/E (x)29.63
RoNW (%)18.20
Company NameSanofi India Ltd.
EPS (Basic)179.46
EPS (Diluted)179.46
NAV (per share) (Rs)373.68
P/E (x)24.47
RoNW (%)48.05
Company NameTorrent Pharmaceuticals Ltd.
EPS (Basic)56.47
EPS (Diluted)56.47
NAV (per share) (Rs)224.28
P/E (x)65.91
RoNW (%)25.18
IPO Reservation
| QIB Shares Offered | 30,58,007 (49.53%) |
| − Anchor Investor Shares Offered | 18,34,804 (29.72%) |
| − QIB (Ex. Anchor) Shares Offered | 12,23,203 (19.81%) |
| NII (HNI) Shares Offered | 9,17,403 (14.86%) |
| − bNII > ₹10L | 6,11,602 (9.91%) |
| − sNII < ₹10L | 3,05,801 (4.95%) |
| Retail Shares Offered | 21,40,606 (34.67%) |
| Employee Shares Offered | 58,035 (0.94%) |
| Total Shares Offered | 61,74,051 (100.00%) |
QIB Shares Offered
30,58,007 (49.53%)
− Anchor Investor Shares Offered
18,34,804 (29.72%)
− QIB (Ex. Anchor) Shares Offered
12,23,203 (19.81%)
NII (HNI) Shares Offered
9,17,403 (14.86%)
− bNII > ₹10L
6,11,602 (9.91%)
− sNII < ₹10L
3,05,801 (4.95%)
Retail Shares Offered
21,40,606 (34.67%)
Employee Shares Offered
58,035 (0.94%)
Total Shares Offered
61,74,051 (100.00%)
Information about company
Incorporated in August 2004, Corona Remedies Limited is a pharmaceutical company developing, manufacturing, and marketing products in women’s healthcare, cardiology, pain management, urology, and other therapeutic areas.
As of June 30, 2025, the company's diverse portfolio includes 71 brands across therapeutic areas like women’s healthcare, cardio-diabeto, pain management, urology, and multispecialty pharmaceuticals (including vitamins/minerals/nutrition, gastrointestinal, and respiratory).
The company has a pan-India marketing and distribution network with 2,671 medical representatives in 22 states, enabling effective engagement with healthcare professionals and hospitals, consolidating its presence in the IPM and ensuring deep penetration in therapeutic areas.
The company has two manufacturing facilities, located in the states of Gujarat with an aggregate installed capacity for formulations of 1,285.44 million units per
annum.
Competitive Strength:
Disclaimer
All matter published here is purely for educational and information purposes only and under no circumstances should be used for making investment decisions.
We are not a SEBI Registered analyst. Readers must consult a qualified financial advisor prior to making any actual investment decisions, based on Information published on this application.
No financial information whatsoever published anywhere, within this application, should be considered as advice to buy or sell securities or invest in IPOs, or as a guide to doing so in any way whatsoever
Please read all Tearms and conditions , and agree to use the App